Structural cardiac or vascular defect

Structural cardiac or vascular defect is a general, non-molecular clinical descriptor referring to a broad range of anatomical abnormalities in the heart or large blood vessels, such as defects in the heart’s valves, walls (septa), chambers, or major vessels[1][2][3][4][5][6][7]. These can be **congenital** (present at birth) or **acquired** later in life due to age, disease (like cardiomyopathy), or injury. Common examples include atrial septal defect (ASD), ventricular septal defect (VSD), heart valve disease (stenosis or regurgitation), coarctation of the aorta, and patent foramen ovale[1][3][6]. Management usually requires interventional cardiology or surgery, often using mechanical devices or prostheses rather than molecular drugs. This term does **not** refer to a single gene product, protein, receptor, enzyme, or molecular target, but to a clinical entity. Therefore, it is not considered a therapeutic target in the conventional molecular/pharmacological sense, and is too broad and unspecific for that purpose.\n\nNote: This entry is inaccurate as a molecular target. The term "Structural cardiac or vascular defect" does not specify a single protein, receptor, enzyme, or druggable entity. Rather, it covers a category of anatomical conditions and cannot be mapped to a unique molecular structure or abbreviation. It should not be listed as a drug target for pharmaceutical development or screening.

Other names

Structural heart defectStructural vascular defectStructural heart disease (SHD)

Mechanical closure or support of septal defects or valves (e.g., occluders)\nReplacement or repair of diseased valves via surgical or transcatheter techniques[2][1][7]